For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230531:nRSe6972Aa&default-theme=true
RNS Number : 6972A Futura Medical PLC 31 May 2023
Block Listing Six Monthly Return
31 May 2023
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products for sexual health and pain relief, makes the following
update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the
AIM Rules for Companies. All figures relate to options over Ordinary Shares of
0.2 pence each (Ordinary Shares).
Date: 30 November 2022
Name of applicant: Futura Medical Plc
Name of scheme(s): Unapproved Share Option Scheme
Unapproved Share Incentive Scheme
EMI Share Option Scheme
LTIP Scheme
Period of return: From: 1 December 2022 To: 31 May 2023
Balance of unallotted securities under scheme(s) from previous return: 6,981,779
Plus: The amount by which the block scheme(s) has been increased since the EMI: 1,100,000
date of the last return (if any increase has been applied for):
LTIP: 4,444,942
Less: Number of securities issued/allotted under scheme(s) during period: USOS: nil
EMI: nil
LTIP: nil
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 12,526,721
Number and class of securities originally admitted and the date of admission USOS Total: 3,882,912
814,424 25 May 2011
1,202,280 8 October 2013
1,466,208 25 May 2017
400,000 30 May 2018
USIS Total: 425,000
425,000 30 November 2018
EMI Total: 8,112,088
1,520,576 25 May 2011
1,467,720 8 October 2013
1,893,792 25 May 2017
790,000 30 May 2018
1,340,000 30 November 2018
1,100,000 2 February 2023
LTIP Total: 4,444,942
4,444,942 2 February 2023
For further information, please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)
Tel: +44 (0) 1483 685 670
www.futuramedical.com (http://www.futuramedical.com/)
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Hollie Vile/ Jonathan Edwards/ Zoe Bolt
Email: futuramedical@optimumcomms.com (mailto:futuramedical@optimumcomms.com)
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Development and commercialisation
strategies are designed to maximise product differentiation and value creation
whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel treatment for
erectile dysfunction ("ED") through a unique evaporative mode of action.
Futura has previously conducted an initial Phase 3 study using MED3000 in ED,
referred to as "FM57" which enabled Futura to be granted a CE Mark in 2021. A
second confirmatory Phase 3 clinical study, "FM71" was also conducted to
support Futura's regulatory submission to the FDA with 96 ED patients and
endpoints at 24 weeks, demonstrating that MED3000 presents an effective
clinically proven treatment for ED with a rapid speed of onset and a
favourable benefit versus risk profile ideally suited for an 'Over the
Counter' classification.
Eroxon® is CE marked in Europe and UKCA marked in the UK as a
clinically proven topical treatment for adult men with erectile dysfunction
under the brand Eroxon® with a key claim of "Helps you get an erection within
10 minutes". Eroxon® is the agreed brand name in certain regions such as the
EU whereas MED3000 continues to be the internal code name used by the Company
and also in reference to countries where regulatory approval or commercial
distribution agreements have not yet been achieved. www.eroxon.com
(http://www.eroxon.com)
Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BLRUVAOROSUVUAR